Adcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease-fighting power of small molecule payloads, Adcentrx strives to develop next-generation targeted therapies for improving patient treatment options.
Status: Private
Aera Therapeutics
Aera’s mission is to unlock the potential of genetic medicines by tackling the greatest unmet need in the field today – delivery. Aera has two proprietary delivery platforms – lipid nanoparticles (LNPs) and protein nanoparticles (PNPs) – that are being developed to enable next-generation genetic medicines across a range of therapeutic modalities and disease areas. These platforms have the potential to overcome the limitations of today’s delivery technologies and expand the application of genetic medicines.
TandemAI
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven and physics-based high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution.
Curie.Bio
Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drug makers, seed capital, and best-of-breed services—everything a founder needs to get from concept to a compelling quality dataset that enables an awesome Series A financing. In a nutshell, we want founders in control of their own company and focused on their area of expertise and creativity, while we help make the rest happen smoothly.
Canoe Intelligence
Canoe’s mission is to unlock efficiencies in alternative investment processes by introducing purpose-built automation into the workflows of institutional investors, asset servicers, capital allocators and wealth managers.
Toku
Toku is a payment orchestration company that offers a solution for collecting recurring payments in LatAm. It has three main value propositions: 1) increase payment acceptance rate via dynamic routing; 2) incur the lowest possible cost by using account-to-account payment; 3) have the best-automated payment experience.
Seis
Seis is banking for the 44 million native Spanish speakers living in the US. Their mission is to build the most delightful, full-service banking experience for anyone who wants to bank in their native Spanish. Their goal is to make such an amazing banking experience that people will wish they spoke Spanish so they could bank with Seis. They’ll treat Spanish speakers as first-class citizens & end “dial 2 for Español”.
Enzene Biosciences Ltd.
Enzene is an innovation-driven biotech company a subsidiary of Alkem Laboratories Ltd. (one of the top five pharmaceutical companies in India*) located in Pune, India. Enzene’s focus lies in producing biosimilars, novel biologics, synthetic peptides and phytopharmaceuticals. Enzene also offers a range of biologics CDMO and CMO services with capabilities from clone development up to GMP manufacturing supported by bio-reactor capacities ranging from 20 litres to 2000 litres.
Shift Bioscience
Shift Bioscience (Shift) is a Cambridge, UK-based biotechnology company focused on safe cellular reprogramming for rejuvenation. The company leverages a proprietary cellular age clock and an active machine learning approach to discover novel factors for safer cellular rejuvenation without the use of pluripotency-inducing reprogramming genes. Shift aims to enable the development of reprogramming-based therapeutics to prevent and treat age-associated diseases.
Paradigm Health
Paradigm is rebuilding the clinical research ecosystem by creating a platform that enables equitable access to trials for all patients, while enhancing trial efficiency and reducing the barriers to participation for healthcare providers. Paradigm aims to break down barriers across the trial ecosystem through one seamless infrastructure implemented at healthcare provider organizations, bringing potentially life-saving therapies to patients faster.